Study to Assess the Bioequivalence Between D961S and Esomeprazole/Buffered Acetylsalicylic Acid (ASA) in Japanese Healthy Male Subjects
Information source: AstraZeneca
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Bioequivalence Study
Intervention: D961S (Drug); Esomeprazole (Drug); Buffered acetylsalicylic acid (Drug)
Phase: Phase 1
Status: Completed
Sponsored by: AstraZeneca
Summary
The purpose of this study is to assess bioequivalence between D961S and
esomeprazole/buffered ASA, safety, tolerability of esomeprazole in combination with ASA and
pharmacokinetics (PK) of D961S, esomeprazole and buffered ASA following repeated
administration in healthy male Japanese subjects.
Clinical Details
Official title: A Phase I, Open Label, Randomized, Single Center, 2 Way Crossover Bioequivalence Study Comparing D961S (a Fixed-dose Combination Capsule of Esomeprazole 20 mg and Acetylsalicylic Acid 81 mg) With a Free Combination of Esomeprazole Capsule 20 mg + Buffered Acetylsalicylic Acid Tablet 81 mg After Repeated Oral Administration in Japanese Healthy Male Subjects
Study design: Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science
Primary outcome: Description of bioequivalence of D961S to combination of esomeprazole + buffered ASA in terms of Area under the plasma concentration(AUCτ).Description of bioequivalence of D961S to combination of esomeprazole + buffered ASA in term maximum plasma concentration (Cmax,ss)
Secondary outcome: Description of D961S PK profile comparing to esomeprazole and ASA combination in terms of AUC0-t,ss, mean residence time (MRT), time to reach Cmax (tmax,ss) and t1/2,ss of esomeprazole and ASA, and AUCτ, Cmax,ss, AUC0-t,ss, MRT, tmax,ss and t1/2,ss of SADescription of Safety and tolerability profile of esomeprazole in combination with ASA in terms of adverse events, clinical laboratory tests, blood pressure, pulse rate and body temperature.
Detailed description:
A Phase I, Open label, Randomized, Single center, 2 way Crossover Bioequivalence Study
Comparing D961S (a Fixed-dose Combination Capsule of Esomeprazole 20 mg and Acetylsalicylic
Acid 81 mg) with a Free Combination of Esomeprazole Capsule 20 mg + Buffered Acetylsalicylic
Acid Tablet 81 mg After Repeated Oral Administration in Japanese Healthy Male Subjects
Eligibility
Minimum age: 20 Years.
Maximum age: 45 Years.
Gender(s): Male.
Criteria:
Inclusion Criteria:
- Healthy Japanese males 20-45 years of age
- Classified as homo-EM
- Negative for HIV, Hepatitis B, Hepatitis C and syphilis
- Body Mass Index (BMI=weight/height2) 19-27 (kg/m2)
- Body weight 50-85 kg
Exclusion Criteria:
- Significant clinical illness from 2 weeks preceding the pre-entry visit to the
randomization
- Past or present cardiac, renal, hepatic, neurological or gastrointestinal disease
- Need for concomitant medication in the study
- Past or present NSAIDs induced asthma
- History of bleeding diathesis
Locations and Contacts
Study site, Hakata, Fukuoka, Japan
Additional Information
Starting date: January 2012
Last updated: April 6, 2012
|